---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-112338"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:59:51.492512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY

## Summary
- Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
- Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.
- Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.
- Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.
- Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025.

## SEC filing metadata
- accession: 0001193125-26-112338
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/0001193125-26-112338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/d34671d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-112338
- JSON: https://secwatch.observer/filing/0001193125-26-112338.json
- Plain text: https://secwatch.observer/filing/0001193125-26-112338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.